
Join to view full profile
1100 Fairview Ave NSeattle, WA 98109
Phone+1 206-667-5000
Dr. Ikeguchi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alexandra Ikeguchi is a medical oncologist based in Seattle, WA with a focus on melanoma. She completed her residency in Internal Medicine and pursued her fellowship in Hematology and Medical Oncology at New York Presbyterian Hospital (Columbia Campus). Dr. Ikeguchi is an Associate Professor at Fred Hutch Cancer Center and the University of Washington Medical Center. She previously served as an Associate Professor at UT MD Anderson Cancer Center and an Assistant Professor at OU Health Stephenson Cancer Center. Her expertise includes melanoma, uveal melanoma, mucosal melanoma, Merkel cell carcinoma, and cutaneous squamous cell carcinoma. Her research has resulted in multiple publications in prestigious journals such as the Journal of Clinical Oncology, Nature Medicine, the New England Journal of Medicine, and Cancer Discovery. She is involved in clinical trials focused on immunotherapy and treatments for various advanced skin cancers, including melanoma and Merkel cell carcinoma.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1995 - 1998
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1992 - 1995
Columbia University Vagelos College of Physicians and SurgeonsClass of 1992
Yale UniversityBS, Chemistry, magna cum laude, distinction in the major, 1984 - 1988
Certifications & Licensure
FL State Medical License 2023 - Present
AZ State Medical License 2023 - 2028
TN State Medical License 2023 - 2028
TX State Medical License 2023 - 2028
WA State Medical License 2023 - 2028
GA State Medical License 2023 - 2027
LA State Medical License 2023 - 2027
American Board of Internal Medicine Hematology- Join now to see all
Clinical Trials
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 Jun 17
- Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 12
Publications & Presentations
PubMed
- 2 citationsCellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1.Katie M Campbell, Daniel G Chen, Zaid E Bustami, Nataly Naser Al Deen, Egmidio Medina
Cancer Discovery. 2026-09-01 - Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.Joshua Herb, Roland L Bassett, Carlos A Torres-Cabala, Victor G Prieto, Sapna P Patel
Annals of Surgical Oncology. 2026-07-01 - Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.Joshua Herb, Roland L Bassett, Carlos A Torres-Cabala, Victor G Prieto, Sapna P Patel
Annals of Surgical Oncology. 2026-07-01
Press Mentions
ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024
Grant Support
- Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell TherapyUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2028
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:



